We recommend testing all patients undergoing cancer treatment for hepatitis B (including HBV surface antigen [HBsAg], HBV core antibody [anti‐HBc], and HBV surface antibody) before cancer treatment.

Individuals with chronic hepatitis B virus (HBV) infection or past exposure to HBV infection have a substantial risk of reactivation during immunosuppressive cancer therapy.

Drug regimens and monitoring The following are medications approved for the treatment of chronic hepatitis B in pediatric and adult patients.

AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.

Testing should include hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc) and hepatitis B surface antibody (anti-HBs).If past or present hepatitis B infection is diagnosed (anti-HBc positive and/or HBsAg positive), the patient should be referred to a doctor with experience in the management of viral hepatitis for consideration of enhanced monitoring and antiviral treatment as appropriate. Abstract.

These services are funded and regulated by the Commonwealth Government and can be operated by not-for-profit, private or state government providers.Assessment services help older people and their carers to identify care that best meets their needs and access Commonwealth Government services for older people.The Home and Community Care Program for Younger People provides funding for services which support frail older people, younger people with disabilities and their carers. Please enable JavaScript in order to get the best experience when using this site. The Victorian Government provides a range of programs to maximise older people’s health and wellbeing and social participation across all life stages.A Victorian government resource providing information and advice on designing and caring for people with dementia in residential aged care settings.

Any queries (other than missing content) should be directed to the corresponding author for the article.Please check your email for instructions on resetting your password.

[This recommendation is from Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B(NICE technology appraisal guidance 96).] Australian and international guidelines recommend that all patients be offered testing for current or resolved hepatitis B infection before undergoing immunosuppression. Residential aged care is for older people who can no longer live at home.

We advocate for broader Medicare Benefits Schedule and Pharmaceutical Benefits Scheme access to HBV testing and treatment for patients undergoing cancer therapy.Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Mircette.

It occurs largely in patients who are hepatitis B surface antigen (HBsAg) positive, but it also occurs in patients with resolved infection who are HBsAg negative but positive for antibody to hepatitis B core antigen (anti‐HBc). Immunosuppressive therapies with increased risk of HBV reactivation include corticosteroids, anthracyclines, rituximab, antibody to tumor necrosis factor and hematopoietic stem cell transplantation.

HBV reactivation can lead to liver failure, cancer treatment interruption or death. Email me when people comment on this article Joseph Doyle receives unrelated investigator‐initiated research grants to his institution from Gilead Sciences, AbbVie, Merck/MSD, and Bristol Myers Squibb; received honoraria to his institution for speaking from Gilead Sciences, Merck/MSD, Bristol Myers Squibb, and AbbVie. Disease Elimination Program, Burnet Institute, Melbourne, VIC Disease Elimination Program, Burnet Institute, Melbourne, VIC AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC Australian Centre for Blood Diseases, Melbourne, VIC Disease Elimination Program, Burnet Institute, Melbourne, VIC Disease Elimination Program, Burnet Institute, Melbourne, VIC AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC Australian Centre for Blood Diseases, Melbourne, VICUse the link below to share a full-text version of this article with your friends and colleagues.

Information and resources to support public hospitals and health services to report their financial data to the department. and you may need to create a new Wiley Online Library account.Enter your email address below and we will send you your usernameIf the address matches an existing account you will receive an email with instructions to retrieve your username J Hepatol 2017;67:370-98. People living with chronic hepatitis B are known to be at risk of reactivation of hepatitis B infection and severe flares of hepatitis in the setting of immunosuppression. Simone Strasser received honoraria for advisory boards and speaking from Gilead Sciences, Bristol‐Myers Squibb, AbbVie, MSD, Norgine, Bayer, Eisai, Ipsen, Pfizer, Astellas and Novartis.